The estimated Net Worth of Charles J. Cohen is at least $317 ezer dollars as of 11 December 2018. Charles Cohen owns over 4,115 units of Xenon Pharmaceuticals Inc stock worth over $316,698 and over the last 10 years Charles sold XENE stock worth over $0.
Charles has made over 2 trades of the Xenon Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Charles exercised 4,115 units of XENE stock worth $12,633 on 11 December 2018.
The largest trade Charles's ever made was exercising 26,748 units of Xenon Pharmaceuticals Inc stock on 12 February 2018 worth over $99,235. On average, Charles trades about 3,429 units every 34 days since 2015. As of 11 December 2018 Charles still owns at least 8,194 units of Xenon Pharmaceuticals Inc stock.
You can see the complete history of Charles Cohen stock trades at the bottom of the page.
Charles's mailing address filed with the SEC is C/O XENON PHARMACEUTICALS INC, 200 - 3650 GILMORE WAY, BURNABY, A1, V5G 4W8.
Over the last 10 years, insiders at Xenon Pharmaceuticals Inc have traded over $12,977,011 worth of Xenon Pharmaceuticals Inc stock and bought 724,015 units worth $2,649,316 . The most active insiders traders include Patrick Machado, Partners L P/Ilbiotechnolog... és Justin D. Gover. On average, Xenon Pharmaceuticals Inc executives and independent directors trade stock every 31 days with the average trade being worth of $818,878. The most recent stock trade was executed by Elizabeth A. Garofalo on 8 March 2024, trading 3,500 units of XENE stock currently worth $64,960.
xenon® (nasdaq: xene) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as extreme genetics. our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits, or phenotypes. we apply our expertise to predict which phenotypes are caused by single-gene defects. by identifying and characterizing the single-gene defects responsible for such severe phenotypes, we gain valuable insights into their function in human biology and their potential as drug targets. given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, we are developing proprietary product candidates to treat both orphan as well as more prevalent diseases.
Xenon Pharmaceuticals Inc executives and other stock owners filed with the SEC include: